Challenges and opportunities in designing clinical trials for neuromyelitis optica

Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Weinshenker, Brian G., Barron, Gerard, Behne, Jacinta M., Bennett, Jeffery L., Chin, Peter S., Cree, Bruce A.C., de Seze, Jerome, Flor, Armando, Fujihara, Kazuo, Greenberg, Benjamin, Higashi, Sayumi, Holt, William, Khan, Omar, Knappertz, Volker, Levy, Michael, Melia, Angela T., Palace, Jacqueline, Smith, Terry J., Sormani, Maria Pia, Van Herle, Katja, VanMeter, Susan, Villoslada, Pablo, Walton, Marc K., Wasiewski, Warren, Wingerchuk, Dean M., Yeaman, Michael R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Views & Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424131/
https://www.ncbi.nlm.nih.gov/pubmed/25841026
http://dx.doi.org/10.1212/WNL.0000000000001520

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4424131/
https://www.ncbi.nlm.nih.gov/pubmed/25841026
http://dx.doi.org/10.1212/WNL.0000000000001520

Ejemplares similares